Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET).
J. A. Chan
Research Funding - Novartis
D. P. Ryan
No relevant relationships to disclose
C. S. Fuchs
Consultant or Advisory Role - Alnylam; Amgen; AVEO; Bristol-Myers Squibb; Enzon; Genentech; Genomic Health; GlaxoSmithKline; ImClone Systems; Roche
A. X. Zhu
Consultant or Advisory Role - Novartis; Pfizer; Sanofi
Research Funding - Bayer
T. A. Abrams
No relevant relationships to disclose
B. M. Wolpin
Research Funding - Novartis
P. Malinowski
No relevant relationships to disclose
E. Regan
No relevant relationships to disclose
M. Kulke
Consultant or Advisory Role - Novartis
Research Funding - Novartis